INST 0601C: A Randomized Phase II Protocol of Erlotinib Versus Standard Platinum-Based Chemotherapy in Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Primary Objective:To compare the activities(the progression-free survival, and the incidence
and severity of toxicities, and reversibility of toxicities) of erlotinib to that of
platinum-based therapy in NSCLC
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective tumor response, clinical benefit, tumor responses + stable disease
disease progress or complete remission
Yes
Dennie V Jones, MD
Principal Investigator
University of New Mexico
United States: Institutional Review Board
INST 0601C
NCT00391586
July 2006
May 2012
Name | Location |
---|---|
University of New Mexico Cancer Center | Albuquerque, New Mexico 87131-5636 |
New Mexico Cancer Care Associates | Santa Fe, New Mexico 87505-7670 |
Hematology Oncology Associates NM | Albuquerque, New Mexico 87106 |
Lovelace Medical Group | Albuquerque, New Mexico 87102 |
Presbyterian Medical Group | Albuquerque, New Mexico 87110 |